1.0樂天醫藥 - Rakuten Medicalhttps://rakuten-med.com/tw樂天醫藥宣布ASP-1929光免疫治療結合抗PD-1免疫製劑之聯合療法期中數據顯示正向的安全性與有效性 - 樂天醫藥 - Rakuten Medicalrich600338<blockquote class="wp-embedded-content" data-secret="08jR1hDTaS"><a href="https://rakuten-med.com/tw/news/press-releases/2023/07/12/7617/">樂天醫藥宣布ASP-1929光免疫治療結合抗PD-1免疫製劑之聯合療法期中數據顯示正向的安全性與有效性</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://rakuten-med.com/tw/news/press-releases/2023/07/12/7617/embed/#?secret=08jR1hDTaS" width="600" height="338" title="“樂天醫藥宣布ASP-1929光免疫治療結合抗PD-1免疫製劑之聯合療法期中數據顯示正向的安全性與有效性” — 樂天醫藥 - Rakuten Medical" data-secret="08jR1hDTaS" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://rakuten-med.com/tw/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
– 18個月整體存活率為53.5% (95%信賴區間 18.5-79.3); 可以耐受的治療副作用 – 提供復發性頭頸癌一種創新的潛在治療選擇 【聖地牙哥訊】樂天醫藥（Rakuten Medical Inc.），一家專注在Alluminox™ 平台上開發精準針對細胞的研究性光免疫治療並將其商業化的全球臨床階段生物技術公司， 於 2023 年 7 月 10 日在美國頭頸協會 (AHNS) […]https://rakuten-med.com/tw/wp-content/uploads/sites/11/2021/02/RakutenMedical_KV.png1500900